-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised brentuximab vedotin for
patients with CD30 positive systemic anaplastic large cell lymphoma
(sALCL).

CD30 positive systemic anaplastic large cell lymphoma and listing dates

CD30 positive systemic anaplastic large cell lymphoma (sALCL) is a rare
type of non-Hodgkin’s lymphoma.

Listing dates are:

-   brentuximab vedotin - 1 December 2014.

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Process written authority approval requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
